Clinical Trial Update: Vildagliptin add-on to Glimepiride Versus Placebo Added to Glimepiride in Type 2 Diabetes [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating add-on vildagliptin to glimepiride versus placebo added to glimepiride in Type 2 diabetes has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Amaryl (glimepiride)
• Galvus (vildagliptin)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: COMPLETED